64 phd-computational-mechanics-"FEMTO-ST"-"FEMTO-ST" positions at MASARYK UNIVERSITY in Czech
Sort by
Refine Your Search
-
Listed
-
Category
-
Program
-
Field
-
research Medical Faculty of Masaryk University, Brno, Czech Republic invites excellent scientists to apply for a two-year POSTDOC POSITION in Computational Cancer Genomics Description: The position is
-
Department: Erik D. Fagerholm Research Group: Computational Neuroscience – Faculty of Medicine Deadline: 31 Jan 2026 Start date: April 2026 or upon agreement Job type: full-time Job field: Science
-
of Science, Masaryk University announces an open competition for the position POSTDOC POSITION in Computational Condensed Matter Physics Workplace: Department of Condensed Matter Physics, Faculty of Science
-
research Come to CEITEC MU in Brno and join us! We are passionate structural biologists at CEITEC looking for PhD Candidate: Ribosomal complexes involved in human translation control About this position
-
for the following position: Assistant Professor in Business Informatics The Department of Business Management at Masaryk University is seeking a highly motivated, experienced full-time or part-time (24 - 40 hours per
-
environment linking molecular biology, biophysics, and computational modeling. Include these in your application: A comprehensive CV detailing your publication history A copy of your PhD diploma Contact
-
grant proposals. Qualifications Successful candidate should have: MSc or PhD in Bioinformatics, Computational Biology, Systems Biology, Computer Science, or related field. Demonstrated experience with
-
on understanding the molecular mechanisms behind retinal development and disease using human pluripotent stem cells. We specialize in creating retinal organoids, “eye-like” organoids, and other retinal cell types
-
are seeking a talented and motivated candidate to join our team to pursue the mechanisms and functions of primary cilia. The primary cilium is an antenna-like organelle that has emerged as a fundamental
-
mutations as risk factors for disease progression therefore has clear clinical implications and benefits for patients and their families. The underlying biological mechanisms leading to leukemic